Tumor vaccine: Current trends in antigen specific immunotherapy

Indian Journal of Experimental Biology

Volumn 43, Issue 5, 2005, Pages 389-406

  Baral, Rathindranath ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

Author keywords

Antibody; Antigen; Immunotherapy; Tumor; Vaccine

Indexed keywords

CANCER VACCINE; TUMOR ANTIGEN;

HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; REVIEW; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 18844388916     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (200)

1. Foon K A, Yannelli J & Bhattacharya-Chatterjee M, Colorectal cancer as a model for immunotherapy, Clin Cancer Res, 5 (1999) 225.
2. Stevanovic S, Identification of tumor associated T-cell epitopes for vaccine development, Nature Reviews, Cancer, 2 (2002) 515.
3. Sidransky D, Emerging molecular markers of cancer, Nature Rev Cancer, 2 (2002) 210.
4. Hoover H C Jr, Peters L C & Brandhorst J S, Therapy of spontaneous metastases with an autologous tumor vaccine in a guinea pig model, J Surg Res, 30 (1981) 409.
5. Conry R M, LoBuglio A F, Loechel F, Moore S E, Surnerel L A, Barlow D L, Pike J & Curiel D T, A carcinoembryonic antigen polynucleotide vaccine for human clinical use, Cancer Gene Ther, 2 (1995) 33.
6. Disis M L, Grabstein K H, Sleath P R & Cheever M A, Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide based vaccine, Clin Cancer Res, 5 (1999) 1289.
7. Bhattacharya-Chatterjee M, Baral R N, Chatterjee S K, Das R, Zeytin, H, Chakraborty M & Foon K A, Counterpoint, cancer vaccine: Single epitope anti-idiotype vaccine versus multiple epitope antigen vaccine, Cancer Immunol Immunother, 49 (2000) 133.
8. Lodge P A, Jones L A, Bader R A, Murphy G P & Salgaller M L, Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial, Cancer Res, 60 (2000) 829.
9. Coley W B, The treatment of inoperable sarcoma with the mixed toxins of erysipelas and Bacillus prodigiosus. Immediate and final results in 140 cases, JAMA, 31 (1898) 389.
10. Atkins M B, Lotze M, Dutcher J P, Fisher R I, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L & Rosenberg S A, High dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated from 1985-1993, J Clin Oncol, 17 (1999) 2105.
11. Rosenberg S A, Yang J C, White D E & Steinberg S M, Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response, Ann Surg, 228 (1998) 307.
12. Kirkwood J M, Strawderman M H, Ernstoff M S, Smith T J, Borden E C & Blum R H, Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial ESR 1684, J Clin Oncol, 14 (1996) 7.
13. Feldman E R, Creagan E T & Schaid D J, Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma, Am J Clin Oncol, 15 (1992) 256.
14. Volkes E E, Fihlin R & Hochster H, A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer, Cancer J, 4 (1998) 46.
15. Motzer R J, Rakhit A & Schwartz L H, Phase I trial of subcutaneous recombinant human interleukins-12 in patients with advanced renal cell cancer, Clin Cancer Res, 4 (1998) 1183.
16. Rini B I, Stadler W M, Spielberger R T, Ratain M J & Vogelzang N J, Granulocyte-macrophage colony stimulating factor in metastatic renal cell carcinoma: a phase II trial, Cancer, 82 (1998) 1352.
17. Fearon E R & Vogelstein B, A genetic model to colorectal carcinogenesis, Cell, 61 (1990) 759.
18. Chakraborty M, Foon K A, Kohler H & Bhattacharya-Chatterjee M, Preclinical evaluation in non-human primates of an anti-idiotypic antibody that mimics carcinoembryonic antigen, J Immunother, 18 (1995) 95.
19. Feneley M R & Partin A W, Diagnosis of localized prostate cancer. 10 years of progress, Curr Op Urol, 10 (2000) 319.
20. Sahin U, Tureci O, Chen Y T, Seitz G, Villena-Heinsen C, Old LJ, Pireundschuh M, Expression of multiple cancer testis (CT) antigens in breast cancer and melanoma: basis for polyvalent cancer testis vaccine strategies, Int J Cancer, 78 (1998) 387.
21. Vidovic D, Graddis T, Chen F, Slagle P, Diegel M, Stepan L & Lau R, Antitumor vaccination with HER2-2-derived recombinant antigens, Int J Cancer, 102 (2002) 660.
22. Kamata M, Denda-Nagai K, Kubota N, Aida S, Takeda K & Irimura T, Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases, Clin Exp Metastasis, 19 (2002) 689.
23. Lee S J, Cho Y S, Cho M C, Shim J H, Lee K A, Ko K K, choe Y K, Park S N, Hoshino T, Kim S, Dinarello C A & Yoon D Y, Both E6 and E7 oncoproteins of human papillomavirus16 inhibit IL-18 induced IFN-gamma production in human peripheral blood mononuclear and NK cells, J Immunol, 167 (2001) 497.
24. Renkvist N, Castelli C, Robbins P F & Parmiani G, A listing of human tumor antigens recognized by T cells, Cancer Immunol Immunother, 50 (2001) 3.
25. Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inone H, Sugimachi K & Mori M, Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas, Br J Cancer, 85 (2001) 713.
26. Werness B A, Levine A J & Howley P M, Association of HPV type 16 and 18 E6 protein with p53, Science (Wash, DC), 248 (1990) 76.
27. Vonderheide R H, Anderson K S, Hahn W C, Butler M O, Schultze J L & Nadler L M, Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase, Clin Cancer Res, 7 (2001) 3343.
28. Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee H G & Rieber E P, Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides, Cancer Res, 60 (2000) 4845.
29. Benchimol S, Fuks A, Jothy S, Beauchemia N, Shirota K & Stanners C, Carcinoembryonic antigen, a human tumor marker functions as an intercellular adhesion molecule, Cell, 57 (1989) 327.
30. Oikawa S, Inuzuka C, Kurori M, Matsuoka Y, Kosaki G & Nakazato H, Cell adhesion activity of non-specific cross-reacting antigen (NCA) and carcinoembryonic antigen (CEA) expressed on CHO cell surface : homophilic and heterophilic adhesion, Biochem Biophys Res Commun, 164 (1989) 39.
31. Bhattacharya-Chatterjee M, Chatterjee S & Foon K A, Anti-idiotype vaccine against cancer, Immunol Lett, 74 (2000) 51.
32. Van der bruggen P, Traversari C, Chomaz P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A & Boon T, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, 254 (1991) 1643.
33. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I & Pfreundschuh M, Human neoplasms elicit multiple specific immune responses in the autologous host, Proc Natl Acad Sci (USA), 92 (1995) 11810.
34. Robbins P F & Kawakami Y, Human tumor antigens recognized by T cells, Curr Opin Immunol, 8 (1996) 628.
35. Pervin S, Chakraborty M, Bhattacharya-Chatterjee M, Zeytin H, Foon K A & Chatterjee S K, Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen, Cancer Res, 57 (1997) 728.
36. Foon K A, Oseroff A R, Vaickus L, Greenberg S J, Russel D, Bernstein Z, Pincus S, Kohler H, Seon B K, Tahaoglu E, Beers T, Chakraborty M & Bhattacharya-Chatterjee M, Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen, Clin Cancer Res, 1 (1995) 1285.
37. Jerne N K, Towards a network theory of the immune system, Ann Immunol (Paris), 125C (1974) 373.
38. Peters L C, Brandhorst J S & Hanna M G Jr, Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors, Cancer Res, 39 (1979) 1353.
39. Hanna M G Jr, Pollack V A & Peters L C, Active-specific immunotherapy of established micrometastases with BCG plus tumor cell vaccines: effective treatment of BCG side effects with isoniazid, Cancer (Phila), 49 (1982) 659.
40. Hoover H C Jr, Brandhorst J S, Peters L C, Surdyke M G, Takeshita Y, Madariaga J, Muenz L R & Hanna M G Jr, Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial, J Clin Oncol, 11 (1993) 390.
41. Morton D L & Barth A, Vaccination therapy for malignant melanoma, CA Cancer J Clin, 46 (1996) 225.
42. Morton D L, Foshag L J & Hoon D S B, Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine, Am Surg, 216 (1992) 463.
43. Morton D L, Hoon D S B & Nizze J A, Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma, Ann NY Acad Sci, 690 (1993) 120.
44. Overett T K & Shiu M H, Surgical treatment of distant metastatic melanoma: Indications and results, Cancer, 56 (1985) 1222.
45. Fenn L G, Gutterman J & Burgess M A, The natural history of respectable metastatic melanoma (Stage IVA melanoma), Cancer, 50 (1982) 1656.
46. Hsueh E C, Essner R, Foshag L J, Ollila D W, Gammon G, O'Day SJ, Boasberg PD, Stern SL, Ye X & Morton DL, Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine, J Clin Oncol, 20 (2002) 4549.
47. Eades-Perner E P, Van der Putten H, Hirth A, Thompson J, Neumaier M, von Kleist S & Zimmermann W, Mice transgenic for human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern, Cancer Res, 54 (1994) 4169.
48. Peat N, Gendler S J, Lalani E N, Duhig T & Taylor-Papadimitriou J, Tissue specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice, Cancer Res, 52 (1992) 1954.
49. Berd D, Herlyn M, Koprowski H & Mastrangelo M J, Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens, Cancer Res, 49 (1989) 6840.
50. Hamilton W B, Helling F, Lloyd K O & Livingston P O, Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography, Int J Cancer, 53 (1993) 566.
51. Livingston P O, Ritter G, Srivastava P, Calves M J, Oettgen H F & Old L J, Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside, Cancer Res, 49 (1989) 7045.
52. Livingston P O, Wong G Y C, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves M J, Helling F, Ritter G, Oettgen H F & Old L J, A randomized trial of adjuvant vaccination with BCG versus BCG plus the melanoma ganglioside GM2 in AJCC stage III melanoma patients, J Clin Oncol, 12 (1994) 1036.
53. Mujoo K, Cheresh D A, Yang H M & Reisfeld R A, Disialoganglioside GD2 on human neuroblastoma cells : target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth, Cancer Res, 47 (1987) 1098.
54. Helling F, Shang A, Calves M J, Zhang S, Ren S, Yu R K, Oettgen H F & Livingston P O, GD3 vaccines for mela noma: superior immunogenicity of KLH conjugate vaccines, Cancer Res, 54 (1994) 197.
55. Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao T J, Panageas K, Moynahan M, Houghton A, Norton L & Livingston P, Vaccination of high risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21, Clin Cancer Res, 6 (2000) 1693.
56. Kirman I, Maydelman A, Asi Z & Whelan R L, Effect of surgical trauma on epithelial cell adhesion molecule (GA-733) vaccine induced tumor resistance, Surg Endosc, 17 (2003) 505.
57. Morse M A, Technology evaluation: Theratope, Biomira Inc, Curr Opin Mol Ther, 2 (2000) 453.
58. Holmberg L A & Sandmaier B M, Theratope vaccine (STn-KLH), Expert Opin Biol Ther, 1 (2001) 881.
59. Ribas A, Timmerman J M, Butterfield L H & Economou J S, Determinant spreading and tumor responses after peptide-based cancer immunotherapy, Trends Immunol, 24 (2003) 58.
60. Sundaram R, Dakappagari N K & Kaumaya P T, Synthetic peptides as cancer vaccines, Biopolymers, 66 (2002) 200.
61. Goydos J S, Elder E, Whiteside T L, Finn O J & Lotze M T, A phase I trial of a synthetic mucin peptide vaccine: induction of specific immune reactivity in patients with adenocarcinoma, J Surg Res, 63 (1996) 298.
62. Domenech N, Henderson R A & Finn O J, Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin, J Immunol, 155 (1995) 4766.
63. Disis M L, Gralow J R, Bernhard H, Hand S L, Rubin W D & Cheever M A, Peptide based, but not whole protein, vaccines elicit immunity to HER2/neu, oncogenic self protein, J Immunol, 156 (1996) 3151.
64. Kiessling A, Schmitz M, Stevanovic S, Weigle B, Holig K, Fussel M, Fussel S, Meye A, Wirth M P & Rieber E P, Prostate stem cell antigen: Identification of immunogenic peptides and assassment of reactive CD8+ T cells in prostate cancer patients, Int J Cancer, 102 (2002) 390.
65. Chatterjee S K, Tripathi P K, Chakraborty M, Yannelli J, Wang H, Foon K A, Maier C C, Blalock J E & Bhattacharya-Chatterjee M, Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody, Cancer Res, 58 (1998) 1217.
66. Kantor J, Irvine K, Abrams S, Kaufman H, Dipietro J & Schlom J, Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine, J Natl Cancer Inst, 84 (1992) 1084.
67. Cooney E L, Collier A C & Greenberg P D, Safety of and immunological response to a recombinant vaccinia virus expressing HIV envelop glycoprotein, Lancet, 337 (1991) 567.
68. Kaufman H, Schlom J & Kantor J, A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA), Int J Cancer, 48 (1991) 900.
69. Bernards R, Destree A & McKenize S, Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector, Proc Natl Acad Sci, USA, 84 (1987) 6854.
70. Hareuveni M, Gautier C & Kien Y, Vaccination against tumor cells expressing breast cancer epithelial tumor antigen, Proc Natl Acad Sci, USA, 87 (1990) 9498.
71. Aarts W M, Schlom J & Hodge J W, Vector-based vaccine/cytokine combination therapy to enhance inducticn of immune responses to a self-antigen and antitumor activity, Cancer Res, 62 (2002) 5770.
72. Greiner J W, Zeytin H, Anver M R & Schlom J, Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity, Cancer Res, 62 (2002) 6944.
73. Poloso N, Nagarajan S, Bumgarner G W, Zampell J C & Selvaraj P, Designer cancer vaccines made easy: protein transfer of immunomodulatory molecules for use in therapeutic tumor vaccines, Front Biosci, 6 (2001) 760.
74. Gitlitz B J, Belldegrum A S & Figlin R A, Vaccine and gene therapy of renal cell carcinoma, Semin Urol Oncol, 19 (2001) 141.
75. Nizard P, Gross D A, Chenal A, Beaumelle B, Kosmatopoulos K & Gillet D, Anchoring cytokines to cancer cells using diphtheria toxin: better than immunotherapy by gene transfer? J Soc Biol, 195 (2001) 229.
76. Cimino A M, Palaniswami P, Kim A C & Selvaraj P, Cancer vaccine development: protein transfer of membrane anchored cytokines and immunostimulatory molecules, Immunol Res, 29 (2004) 231.
77. Nagarajan S & Selvaraj P, Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response, Cancer Res, 62 (2002) 2869.
78. Townsend S E & Allison J P, Tumor rejection after direct co-stimulation of CD8+ T cells by B7-transfected melanoma cells, Science, 259 (1993) 368.
79. Yiwen Li, Hellstrom K E, Newby S A & Chen L, Co-stimulation by CD 48 and B7-1 induces immunity against poorly immunogenic tumors, J Exp Med, 183 (1996) 639.
80. Steller M A, Cervical cancer vaccines: progress and prospects, J Soc Gynecol Invest, 9 (2002) 254.
81. Bubenik J, Therapeutic vaccines against HPV 16-associated tumors, Neoplasma, 49 (2002) 285.
82. Kim T Y, Myoung H J, Kim J H, Moon I S, Kim T G, Ahn W S & Sin J I, Both E7 and CpG-Oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus16 (E6/E7) immortalized tumor cells : Involvement of CD4+ and CD8+ T cells in protection, Cancer Res, 62 (2002) 7234.
83. Disis M L, Shiota F M & Cheever M A, Human Her-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for "self" tumor antigens, Immunology, 93 (1998) 192.
84. Sioud M & Sorensen D, Generation of an effective antitumor immunity after immunization with xenogenic antigens, Eur J Immunol, 33 (2003) 38.
85. Guevara-Patino J A, Turk M J, Wolchok J D & Houghton A N, Immunity to cancer through immune recognition of altered self: studies with melanoma, Adv Cancer Res, 90 (2003) 157.
86. Gregor P D, Wolchok J D, Ferrone C R, Buchinshky H, Guevara-Patino J A, Perales M A, Mortazavi F, Bacich D, Heston W, Latouche J B, Sadelain M, Allison J P, Scher H I & Houghton A N, CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems, Vaccine, 22 (2004) 1700.
87. Lindenmann J, Speculations on idiotypes and homebodies, Ann Immunol (Paris), 124 (1973) 171.
88. Foon K A, Lutzky J, Baral R N, Yannelli J R, Hutchins L, Teitelbaum A, Kashala O L, Das R, Garrison J, Reisfeld R A & Bhattacharya-Chatterjee M, Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2, J Clin Oncol, 18 (2000) 376.
89. Durrant L G, Buckley T J D, Denton G W L, Hardcastle J D, Sewell H F & Robins R A, Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7, Cancer Res, 54 (1994) 4837.
90. Chakraborty M, Foon K A, Kohler H & Bhattacharya-Chatterjee M, Preclinical evaluation in non-human primates of an anti-idiotypic antibody that mimics carcinoembryonic antigen, J Immunother, 18 (1995) 95.
91. Reece D E, Foon K A, Chatterjee M B, Adkins D, Broun E R, Connaghan D G, Dipersio J F, Holland H K, Howard D A, Hale G A, Klingemann H G, Munn R K, Raptis A & Phillips G L, Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer, Clin Breast Cancer, 3 (2003) S152.
92. Herlyn D, Somasundaram R, Li W, Maruyama H, anti-idiotype cancer vaccines: past and future, Cancer Immunol Immunother, 43 (1996) 65.
93. Weigle W O, The immune response of rabbits tolerant to bovine serum albumins, J Exp Med, 114 (1961) 111.
94. Foon K A & Bhattachary-Chatterjee M, Idiotype vaccines in the clinic, Nature Med, 4 (1998) 70.
95. Raychoudhuri S, Saeki Y, Fuji H & Kohler H, Tumor Specific Idiotype Vaccines I Generation and characterization of internal image tumor antigen, J Immunol, 137 (1986) 1743.
96. Raychoudhuri S, Saeki Y, Chen J J, Tribe H, Fuji H & Kohler H, Tumor Specific Idiotype Vaccines II Analysis of the tumor-related network response induced by the tumor and by internal image antigens (Ab2β), J Immunol, 139 (1987) 271.
97. Chen J J, Saeki Y, Shi L & Kohler H, Synergistic antitumor effects with combined "internal image" anti-idiotypes and chemotherapy, J Immunol, 143 (1989) 1053.
98. Bhattacharya-Chatterjee M, Baral R N, Saha A, Pal S, Foon K A, Primus F J & Chatterjee S K, Induction of protective immunity by an anti-idiotype antibody vaccine mimicking carcinoembryonic antigen in mice transgenic for human carcinoembryonic antigen, Int J Cancer, 13S (2002) 157.
99. Kennedy R C, Dreesman G R, Butel J S & Lanford R E, Suppression of in vivo tumor formation induced by simian virus 40-transformed cells in mice receiving anti-idiotypic antibodies, J Exp Med, 161 (1985) 1432.
100. Nelson K A, George E, Swenson C, Forstrom J W & Hellstrom K E, Immunotherapy of murine sarcomas with auto-anti-idiotypic monoclonal antibodies which bind to tumor specific T cells, J Immunol, 139 (1987) 2110.
101. Ruiz P J, Immunity to mutant p53 and tumor rejection induced by idiotypic immunization, Nature Med, 4 (1998) 710.
102. Seon B K, Negoro S, Barcos M P, Tebbi C K, Chervinsky D & Fukukawa T, Monoclonal antibody SN2 defining a human T-cell leukemia-associated cell surface glycoprotein, J Immunol, 132 (1984) 2089.
103. Chakraborty M, Mukherjee S, Foon K A, Kohler H, Ceriani R L & Bhattacharya-Chatterjee M, Induction of human breast cancer-specific antibody responses in Cynomolgus monkeys by a murine monoclonal anti-idiotype antibody, Cancer Res, 55 (1995) 1525.
104. Bhattacharya-Chatterjee M, Das R, Sen G, Baral R N, Ceriani R L, Munn R K & Foon K A, Immune responses in breast cancer patients treated with an anti-idiotype antibody vaccine that mimics human milk fat globule (HMFG) membrane antigen, AntiCancer Res, 18 (1998) 4835.
105. Reece D E, Foon K A, Chatterjee M B, Adkins D, Broun E R, Connaghan D G, Dipersio J F, Holland H K, Howard D A, Hale G A, Klingemann H G, Munn R K, Raptis A & Phillips G L, Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer, Clin Breast Cancer, 3 (2003) S152.
106. Gaida F J, Fenger U, Wagener C & Neumaier M, A monoclonal anti-idiotypic antibody bearing the image of an epitope specific to the human carcinoembryonic antigen, Int J Cancer, 51 (1992) 459.
107. Losman M J, Monestier M, Hansen H J & Goldenberg D M, Baboon anti-idiotype antibodies mimic a carcinoembrynic antigen epitope, Int J Cancer, 46 (1990) 310.
108. Losman M J, Novick K E, Goldenberg D M & Monestier M, Mimicry of a carcinoembrynic antigen epitope by a rat monoclonal anti-idiotype antibody, Int J Cancer, 56 (1990) 580.
109. Bhattacharya-Chatterjee M, Mukherjee S, Biddle W, Foon K A & Heinz K, Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen, J Immunol, 145 (1990) 2758.
110. Foon K A, Chakraborty M, John W J, Sherratt A, Heinz K & Bhattacharya-Chatterjee M, Immune response to the carcinoembryonic antigen in patients treated an anti-idiotype antibody vaccine, J Clin Invest, 96 (1995) 334.
111. Foon K A, John W J, Chakraborty M, Sherratt A, Garrison J, Flett M & Bhattacharya-Chatterjee M, Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics carcinoembryonic antigen, Clin Cancer Res, 3 (1997) 1267.
112. Foon K A, John W J, Chakraborty M, Das R, Teitelbaum A, Garrison J, Kashala O, Chatterjee S K & Bhattacharya-Chatterjee M, Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics carcinoembryonic antigen, J Clin Oncol, 17 (1999) 2889.
113. Tripathi P K, Qin H, Deng S, Bhattacharya-Chatterjee M, Foon K A & Chatterjee S K, Antigen mimicry by an anti-idiotypic antibody single-chain variable fragment, Mol Immunol, 35 (1998) 853.
114. Fagerberg J, Steinitz M, Wigzell H, Askelof P & Mellstedt H, Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients, Proc Natl Acad Sci, USA, 92 (1995) 4773.
115. Durrant L G, Doran M, Austin E B & Robins R A, Induction of cellular immune responses by a murine monoclonal anti-idiotypic antibody recognizing the 791Tgp72 antigen expressed on colorectal, gastric and ovarian human tumours, Int J Cancer, 61 (1995) 62.
116. Denton G W L, Durrant L G, Hardcastle J D, Austin E B, Sewell H F & Robins R A, Clinical outcome of colorectal cancer patients immunized with human monoclonal anti-idiotypic antibody, Int J Cancer, 57 (1994) 10.
117. Durrant L G, Buckley T J D, Denton G W L, Hardcastle J D, Sewell H F & Robins R A, Enhanced cell-mediated tumor killing in patients immunized with human monoclonal anti-idiotypic antibody 105AD7, Cancer Res, 54 (1994) 4837.
118. Chapman P B, Livingston P O, Morrison M E, Immunization of melanoma patients with anti-idiotypic monoclonal antibody BEC2 which mimics GD3 ganglioside: Pilot trials using no immunological adjuvant, Vaccine Res, 3 (1994) 59.
119. McCaffery M, Yao T J & Williams A, Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant, Clin Cancer Res, 2 (1996) 619.
120. Sen G, Chakraborty M, Foon K A, Reisfeld R A & Bhattacharya- Chatterjee M, Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2, J Immunother, 21 (1998) 75.
121. Foon K A, Sen G, Hutchins L, Kashala O L, Baral R, Banerjee M, Chakraborty M, Garrison J, Reisfeld R A & Bhattacharya-Chatterjee M, Antibody responses in melanoma patients immunized with an anti-idiotype mimicking disialoganglioside GD2, Clin Cancer Res, 4 (1998) 1117.
122. Foon K A, Lutzky J, Baral R N, Yannelli J R, Hutchins L, Teitelbaum A, Kashala O L, Das R, Garrison J, Reisfeld R A & Bhattacharya-Chatterjee M, Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2, J Clin Oncol, 18 (2000) 376.
123. Baral R N, Sherrat A, Das R, Foon K A & Bhattacharya-Chatterjee M, Murine Monoclonal Anti-Idiotype Antibody as a surrogate Antigen for human Her2/neu, Int J Cancer, 92 (2001) 88.
124. Dredge K, Marriott J B, Todryk S M & Dalgleish A G, Adjuvants and promotion of Th1-type cytokines in tumor immunotherapy, Cancer Immunol Immunother, 51 (2002) 521.
125. Audibert F M & Lise L D, Adjuvants: Current Status, clinical perspective and future prospects, Immunol Today, 15 (1993) 281.
126. Kensil C R, Patel U, Lennick M & Marciani D, Separation and characterization of Saponins with adjuvant activity from Quillaja Saponaaria Molina Cortex, J Immunol, 146 (1991) 431.
127. Lipford G B, Bauer M, Blank C, Reiter R, Wagner H & Heeg K, CpG containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen-A new class of vaccine adjuvants, Eur J Immunol, 27 (1997) 2340.
128. Kawarada Y, Ganss, R, Garbi N, Sacher T, Amold B & Hammerling G J, NK- & CD8(+) T cell mediated eradicatior of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides, J Immunol, 167 (2001) 5247.
129. Yamamoto S, Yamamoto T, Shimada T, Kuramoto E, Yanc O, Kataoka T & Tokunaga T, DNA from bacteria, but not vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth, Microl Immunol, 36 (1992) 983.
130. Klinman D M, Yi A K, Beaucage S L, Conover J & Krieg A M, CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon-γ, Proc Natl Acad Sci, USA, 93 (1996) 2879.
131. James S L & Pearce E J, The influence of adjuvant on induction of protective immunity by a nonliving vaccine against schistosomiasis, J Immunol, 140 (1988) 2753.
132. Steiner J W, Langer B & Schatz D L, The local and systemic effects of Freund's adjuvant and its fractions, Arch Pathol, 70 (1960) 424.
133. Cox J C & Coulter A R, Adjuvants: A classification and review of their modes of action, Vaccine, 15 (1997) 248.
134. Livingston P O, Wong G Y C & Adluri S, Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside, J Clin Oncol, 12 (1994) 1036.
135. Weiner G J, Liu H M, Wooldridge J E, Dahle C E & Krieg A M, Immunostimulatory oligonucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization, Proc Natl Acad Sci, USA, 94 (1997) 10833.
136. Liu W M, Bally M B & Schutze-Redelmeier M P, Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes, Vaccine, 20 (2001) 148.
137. Corral R S & Petray P B, CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi, Vaccine, 19 (2000) 234.
138. Wooldridge J E, Ballas Z, Krieg A M & Weiner G J, Immunostimulatory oligonucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma, Blood, 89 (1997) 2994.
139. Baral R N, Saha A, Chatterjee S, Foon K A, Krieg A M, Weiner G J & Bhattacharya-Chatterjee M, Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen, Cancer Immunol Immunother, 52 (2003) 317.
140. Fagerberg J, Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy, Med Oncol, 13 (1996) 155.
141. Stritzke J, Zunkel T, Stteinmann J, Schmitz N, Uharek L & Zeis M, Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model, Br J Haematol, 120 (2003) 27.
142. Weber J, Sondak V K, Scotland R, Philip R, Wang F, Rubio V, Stuge T B, Groshen S G, Gee C, Jeffery G G, Sian S & Lee P P, Granulocyte macrophage colony stimulating factor added to a multipeptide vaccine for resected stage II melanoma, Cancer, 97 (2003) 186.
143. 37Ra complexed in different adjuvants, Indian J Exp Biol, 39 (2001) 1227.
144. Steinman R M, The dendritic cell system and its role in immunogenicity, Ann Rev Immunol, 9 (1991) 271.
145. Hart D N J, Dendritic cells: unique leukocyte populations which control the primary immune response, Blood, 90 (1997) 3245.
146. Inaba K, Metlay J P, Crowely M T & Steinman R M, Dendritic cells pulsed with protein antigen in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med, 172 (1990) 631.
147. Dubois B, Vanbervliet B, Fayette J, Massacrier C, Van Kooten C, Briere F, Banchereau J & Caus C, Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes, J Exp Med, 185 (1997) 941.
148. Inaba K, Witmer M D & Steinman R M, Clustering of dendritic cells, helper T lymphocytes, and histocompatible B cells, during primary antibody responses in vitro, J Exp Med, 160 (1984) 858.
149. Gatza E & Okada C Y, Tumor cell lysate pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma, J Immunol, 169 (2002) 5227.
150. Fields R C, Shimizu K & Mule J J, Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune response in vitro and in vivo, Proc Natl Acad Sci, USA, 95 (1998) 9482.
151. Mayordomo J I, Zorina T, Storkus W J, Zitvogel L, Celluzzi C, Falo L D, Melief C J, Ildstad S T, Kast W M, Deleo A B & Lotze M T, Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity, Nature Med, 1 (1995) 1297.
152. Paglia P, Chiodoni C, Rodolfo M & Colombo M P, Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo, J Exp Med, 183 (1996) 317.
153. Saha A, Chatterjee S K, Foon K A, Primus F J & Bhattacharya- Chatterjee M, Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity, Cancer Res, 63 (2003) 2844.
154. Trapani J A, Davis J, Sutton V R & Smyth M J, Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo, Curr Opin Immunol, 12 (2000) 323.
155. Kagi D B, Ledermann K, Burki R M, Zinkernagel R M & Hengartner H, Molecular mechanisms of lymphocyte mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo, Ann Rev Immunol, 14 (1996) 207.
156. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, Longenecker B M, Yao T J, Oettgen H F & Livingston P O, GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21, Cancer Res, 55, 1995, 2783.
157. Ragupathi J, Meyers M, Adluri S, Howard L, Musselli C & Livingston P O, Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-Lactone-KLH conjugate plus immunological adjuvant QS-21, Int J Cancer, 85 (2000) 659.
158. Livingston P O, Wong G Y C, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves M J, Helling F, Ritter G, Oettgen H F & Old L J, Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside, J Clin Oncol, 12 (1994) 1036.
159. Chattopadhyay J, Chatterjee R, Chattopadhyay U & Roy Chowdhury J, Purification and partial characterization of a murine mammary tumor associated antigen, GANN, 75 (1984) 334.
160. Chattopadhyay J, Chatterjee R, Chattopadhyay U & Roy Chowdhury J, Immunological relatedness of a murine mammary tumor associated antigen and human breast cancer, GANN, 75 (1984) 342.
161. Pal S, Sanyal U & Chattopadhyay U, Purification and characterization of an 85 kDa glycoprotein antigen from human breast tumor, Int J Cancer, 60 (1995) 759.
162. Chattopadhyay U & Pal S, A new 85 kDa breast tumor associated antigen, J Biosci, 22 (1997) 69.
163. Das S, Bose S R, Chattopadhyay U & Roychowdhury J, Tumor associated antigens in pre-menopausal and post-menopausal cervical carcinoma, IRCS Med Sci, 9 (1981) 903.
164. Das S, Chatterjee R, Chattopadhyay U & Roychowdhury J, Partial purification and characterization of tumor associated antigen in cervical carcinoma, Neoplasma, 32 (1985) 21.
165. Das S, Bal N, Roychowdhury J & Chattopadhyay U, Immunoglobulins, immune complexes and antitumor antibodies as prognostic indicators in carcinoma of uterine cervix, J Exp Clin Cancer Res, 12 (1993) 91.
166. Bhatnagar J, Tewari H B, Bhatnagar M & Austin G E, Comparison of carcinoembryonic antigen in tissue and serum with grade and stage of colon cancer, Anticancer Res, 19 (1999) 2181.
167. Bhatavdekar J M, Trivedi S N, Shah N G, Patel D D, Karelia N H, Shukla M K, Ghosh N & Vora H H, Comparison of prolactin, CA 15-3 and TPA in breast carcinomas, Int J Biol Markers, 4 (1989) 150.
168. Muthuswamy S & Raste A S, Clinical significance of cancer antigen, CA 15.3 in breast.cancer, Ind J Med Sci, 54 (2000) 442.
169. Hill P G, Johnson S & Madanagopalan N, serum alpha-fetoprotein and hepatitis B antigen in subjects with hepatoma in south India, Indian J Med Res, 65 (1977) 482.
170. Ralhan R, Arora S, Chattopadhyay T K, Shukla N K & Mathur M, circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India, Int J Cancer, 85 (2000) 791.
171. Ralhan R, Swain R K, Agarwal S, Kaur J, Nath N, Sarkar G, Mathur M & Shukla N K, P-glycoprotein is positively correlated with p53 in human oral premalignant and malignant lesions and is associated with poor prognosis, Int J Cancer, 84 (1999) 80.
172. Nayak B K, Baral R N & Das B R, p53 gene mutation in relation to p53 protein accumulation in male and female breast cancer, Neoplasma, 43 (1996) 305.
173. Nayak B K & Das B R, Differential binding of nuclear proteins to the TP53 gene promoter in male breast cancer, Eur J Cancer, 33 (1997) 1484.
174. Nayak B K, Patnaik S & Das B R, Rearrangement of the p53 gene in human breast tumors, Biochem Biophys Res Commun, 245 (1998) 388.
175. Nayak B K & Das B R, Mutation and methylation status of p53 gene promoter in human breast tumours, Tumour Biol, 20 (1999) 341.
176. Nayak B K & Das B R, Differential binding of NF1 transcription factor to P53 gene promoter and its depletion in human breast tumours, Mol Biol Rep, 26 (1999) 223.
177. Sahu G R, Nayak B K, Patnaik S, Patija T & Das B R, Rearrangement of p53 gene with overexpressed p53 protein in primary cervical cancer, Oncol Rep, 9 (2002) 433.
178. Damodaran A, Gangal S G, Pichan D, Amin K, Fakih A R, Jambhekar N, Rao R & Chiplunkar S V, Analysis of DNA ploidy and expression of tumour-associated antigens on human oral carcinomas xenografted in nude mice, Oral Oncol, 33 (1997) 402.
179. Desai S A, Maniar H S, Rao R S, Fakih A R & Gangal S G, Modulatory effect of cytokines on natural killer and antibody dependent cellular cytotoxicity directed to squamous cell carcinoma targets by lymphocytes from oral cancer patients, Eur J Cancer B Oral Oncol, 29B (1993) 69.
180. Maniar H S, Desai S A, Chiplunkar S V, Amin M K, Rao R S & Gangal S G, Modulation of tumor associated antigen expressed on human squamous cell carcinoma cell lines by recombinant interferon-alpha, Eur J Cancer B Oral Oncol, 29B (1993) 57.
181. Abdulkader M, Ravindran A, Sudha L, Vijaykumar T & Vasudevan D M, Demonstration of a tumour associated antigen in human oral cancers, Indian J Med Res, 74 (1981) 428.
182. Vijaykumar T, Sasidharan V K, Ankathil R, Remani P, Kumari T V & Vasudevan D M, Incidence of hepatitis B surface antigen (HBsAg) in oral cancer and carcinoma of uterine cervix, Indian J Med Res, 21 (1984) 7.
183. Kumari T V, Harikumar T, Prabha B, Sasidharan V K & Vasudevan D M, Detection of antibodies against herpes simplex virus in patients with oral cancer, Indian J Cancer, 21 (1984) 137-140.
184. Kumari T V, Shanmugam J, Prabha B & Vasudevan D M, Prevalence of antibodies against herpes simplex and adenovirus in oral and cervical cancer patients-A preliminary report, Indian J Med Res, 75 (1982) 590.
185. Pillay M, Vasudevan D M, Rao C P & Vidya M, p53 expression in oral cancer: observations of a South Indian study, J Exp Clin Cancer Res, 22 (2003) 447.
186. Talwar G P, Singh O, Pal R, Chatterjee N, Suri A K & Shaha C, Vaccines for control of fertility, Indian J Exp Biol, 30 (1992) 947.
187. Talwar G P, Singh O, Pal R, Chatterjee N, Vaccines for control of fertility and hormone dependent cancers, Int J Immunopharmacol, 14 (1992) 511.
188. Ray P K, Bacterial neuraminidase and altered immunological behavior of treated mammalian cells, Adv Appl Microbiol, 21 (1977) 227.
189. Baral R N & Chattopadhyay U, Neem (Azadirachta indica) leaf mediated immune activation causes prophylactic growth inhibition of murine Ehrlich carcinoma and B16 melanoma, Int Immunopharmacol, 4 (2004) 355.
190. Vermoken J B, Claessen A M & Van Tinteren H. Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial, Lancet, 353 (1999) 345.
191. Wallack M K, Sivanandham M & Balch C M, Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial, J Am Coll Surg, 187 (1998) 69.
192. Marchand M, Weynants P & Rankin E, Tumor regression responses in melanoma patients treated with a peptide encoded by gene AGE-3, Int J Cancer, 63 (1995) 883.
193. Scheibenbogen C, schmittel A & Keilholz U, Vaccination with tyrosinase peptides and GMCSF in metastatic melanoma: a phase II trial, Proc Am Soc Clin Oncol, 18 (1999) 436a.
194. Weber J, Jeffery G & Marty V, Phase II trial of GP100/tyrosinase peptides/IFA with and without IL-12 for resected stages III/IV melanoma, Proc Am Soc Clin Oncol, 19 (2000) 455a.
195. Murphy G P, Tjoa B A & Simmons S J, Infusion of dendritic cells pulsed with HLA-A2-specific prostate specific membrane antigen peptides; a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease, Prostate, 38 (1999) 73.
196. Lim S H & Baily-Wood R, Idiotypic protein pulsed dendritic cell vaccination in multiple myeloma, Int J Cancer, 83 (1999) 215.
197. Weber J, Jeffery G & Marty V, A phase I trial of GP100/tyrosinase peptide-pulsed dendritic cells for metastatic melanoma, Proc Am Soc Clin Oncol, 18 (1999) 432a.
198. Cobleigh M A, Vogel C L, Tripathy D, Robert N J, Scholl S & Fehrenbacher L, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J Clin Oncol, 17 (1999) 2639.
199. McLaughlin P, Grillo-Lopez A J & Link B K, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program, J Clin Oncol, 16 (1998) 2825.
200. Witzig T E, White C A & Wiseman E A, Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin,s lymphoma, J Clin Oncol, 17 (1999) 3793.